't zal maar gebeuren schreef op 6 september 2012 15:13:
[...]
je mag zelf ook wel wat moeite doen.:-)
Leiden, The Netherlands, September 5, 2012. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announces that it has called the second tranche of 16,000,000 shares under the €10 million equity working capital facility previously announced on August 1, 2012. Alongside, Pharming reports that the pivotal Phase III Study (Study 1310) of RUCONEST® is now entering its last weeks prior to completion, with 71 out of 75 patients either treated for a subsequent attack of HAE or reaching the Day 90 endpoint of the study.
Sijmen de Vries, Pharming’s CEO commented: “With this second tranche of our equity working capital facility we would expect to be able to complete Study 1310 and analyse the primary endpoint results. The completion of the study is now weeks away and we are focusing on minimizing the time needed, after completion, to close the database and perform the primary endpoint analysis.”
Pharming has the option to draw from the working capital facility in tranches, in exchange for ordinary shares in the capital of the Company, with the timing and the amount of any tranche determined by Pharming. The number of shares now issued by Pharming to the participating investors amounts to 16,000,000. The individual investors have an option to purchase up to 600% of the number of shares to be issued during the 15 trading days pricing period; the total amount of cash paid for such shares to Pharming will depend on the total number of shares called by the investors and the development of the Volume Weighted Average Price (VWAP) of the shares going forward during this 15 trading days pricing period. SHORT SELLING IS NOT PERMITTED UNDER THE AGREEMENT.
---------------------------------------------------